JAGX Quote, Financials, Valuation and Earnings

iBio has a net margin of -317.05% compared to Jaguar Health's net margin of -4444.57%. Jaguar Health's return on equity of -394.73% beat iBio's return on equity of -148.3%.

Jaguar Health has a consensus price target of $14.50, signalling upside risk potential of 538.57%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Jaguar Health has higher upside potential than iBio, analysts believe Jaguar Health is more attractive than iBio.

Jaguar Health has a beta of 0.894, which suggesting that the stock is 10.646% less volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.

Jaguar Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.

Jaguar Health quarterly revenues are $3.1M, which are larger than iBio quarterly revenues of $175K. Jaguar Health's net income of -$9.9M is lower than iBio's net income of -$4M. Notably, Jaguar Health's price-to-earnings ratio is -- while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health is 0.35x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -317.05% compared to Jaguar Health's net margin of -49.65%. Jaguar Health's return on equity of -394.73% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Jaguar Health has a consensus price target of $14.50, signalling upside risk potential of 538.57%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Jaguar Health, analysts believe NovaBay Pharmaceuticals is more attractive than Jaguar Health.

Jaguar Health has a beta of 0.894, which suggesting that the stock is 10.646% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Jaguar Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Jaguar Health quarterly revenues are $3.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Jaguar Health's net income of -$9.9M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Jaguar Health's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health is 0.35x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -317.05% compared to Jaguar Health's net margin of -2357.27%. Jaguar Health's return on equity of -394.73% beat Palatin Technologies's return on equity of --.

Jaguar Health has a consensus price target of $14.50, signalling upside risk potential of 538.57%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Jaguar Health, analysts believe Palatin Technologies is more attractive than Jaguar Health.

Jaguar Health has a beta of 0.894, which suggesting that the stock is 10.646% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Jaguar Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Jaguar Health quarterly revenues are $3.1M, which are larger than Palatin Technologies quarterly revenues of $350K. Jaguar Health's net income of -$9.9M is lower than Palatin Technologies's net income of -$7.8M. Notably, Jaguar Health's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health is 0.35x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -317.05% compared to Jaguar Health's net margin of --. Jaguar Health's return on equity of -394.73% beat Theriva Biologics's return on equity of --.

Jaguar Health has a consensus price target of $14.50, signalling upside risk potential of 538.57%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 7838.6%. Given that Theriva Biologics has higher upside potential than Jaguar Health, analysts believe Theriva Biologics is more attractive than Jaguar Health.

Jaguar Health has a beta of 0.894, which suggesting that the stock is 10.646% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

Jaguar Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jaguar Health pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Jaguar Health quarterly revenues are $3.1M, which are larger than Theriva Biologics quarterly revenues of --. Jaguar Health's net income of -$9.9M is lower than Theriva Biologics's net income of -$7.7M. Notably, Jaguar Health's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jaguar Health is 0.35x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.